Abstract
Thrombolytic therapy with alteplase in acute ischemic stroke is currently established within 3 h from symptom onset in carefully selected patients. Expansion of the time window is being assessed in trials with alteplase and desmoteplase. Also, tenecteplase, reteplase and staphylokinase are being evaluated in stroke patients. A better understanding of the coagulation and fibrinolytic systems may provide insight into drug development, interactions, complications, and may ultimately improve patient triage and treatment regimens. Future adjuvant and additional therapies could prove useful for patients who do not benefit from standard thrombolytic treatment or may augment the overall gain.
Keywords: Thrombolytic therapy, stroke, cerebral infarction, t-PA, thrombolysis, hemorrhage, recanalization, thrombosis
Current Vascular Pharmacology
Title: Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Volume: 4 Issue: 1
Author(s): Atte Meretoja and Turgut Tatlisumak
Affiliation:
Keywords: Thrombolytic therapy, stroke, cerebral infarction, t-PA, thrombolysis, hemorrhage, recanalization, thrombosis
Abstract: Thrombolytic therapy with alteplase in acute ischemic stroke is currently established within 3 h from symptom onset in carefully selected patients. Expansion of the time window is being assessed in trials with alteplase and desmoteplase. Also, tenecteplase, reteplase and staphylokinase are being evaluated in stroke patients. A better understanding of the coagulation and fibrinolytic systems may provide insight into drug development, interactions, complications, and may ultimately improve patient triage and treatment regimens. Future adjuvant and additional therapies could prove useful for patients who do not benefit from standard thrombolytic treatment or may augment the overall gain.
Export Options
About this article
Cite this article as:
Meretoja Atte and Tatlisumak Turgut, Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts, Current Vascular Pharmacology 2006; 4 (1) . https://dx.doi.org/10.2174/157016106775203108
DOI https://dx.doi.org/10.2174/157016106775203108 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care
Current Hypertension Reviews Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
Current Drug Metabolism Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Stem Cell Therapy in Heart Diseases: A Review of Selected New Perspectives,Practical Considerations and Clinical Applications
Current Cardiology Reviews Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents Anesthesia and Postoperative Cognitive Dysfunction (POCD)
Central Nervous System Agents in Medicinal Chemistry Prevention of Bioprosthetic Heart Valve Calcification: Strategies and Outcomes
Current Medicinal Chemistry Drug-Like Inhibitors of Protein-Protein Interactions: A Structural Examination of Effective Protein Mimicry
Current Protein & Peptide Science Dietary Transition in the South Asian Diaspora: Implications for Diabetes Prevention Strategies
Current Diabetes Reviews Review of Trans-Atlantic Cardiovascular Best Medical Therapy Guidelines – Recommendations for Asymptomatic Carotid Atherosclerosis
Current Vascular Pharmacology Inflammatory Markers in Coronary Artery Disease: Pathophysiological Mechanisms, Prognostic and Therapeutic Implications
Current Cardiology Reviews Hypertensive Left Ventricular Hypertrophy Regression: Does It Matter?
Current Hypertension Reviews The Concept of Depression as a Dysfunction of the Immune System
Current Immunology Reviews (Discontinued) Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
Current Vascular Pharmacology Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Endothelial Therapy of Atherosclerosis and its Risk Factors
Current Vascular Pharmacology Blood Serum Atherogenicity and Coronary Artery Calcification
Current Pharmaceutical Design Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?
Current Drug Therapy Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation
Current Vascular Pharmacology Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets